NeOnc Technologies Holdings Inc. has appointed Dr. Josh Neman as Chief Clinical Officer. Dr. Neman, previously associated with the University of Southern California, will lead the company's clinical development strategy, focusing on accelerating clinical trials, particularly the lead asset NEO100. His role will also involve expanding research collaborations and integrating AI and quantum computing into the drug delivery platform.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.